The UK’s European university Moving the fruits of our research into the real world - 8 th January 2018 Challenges, Opportunities & Prospects Professor David Wilkinson Professor of Psychology
Setting the scene – why should we bother? The Problem “An ageing population that lives longer but not necessarily in better health; rising health inequalities; the increasing influence of unhealthy lifestyle choices; increases in the burden of mental health; the future threat of changing patterns of infectious an respiratory disease, in part due to antimicrobial resistance and air pollution”. Futures Health Survey, Rand Corporation, 2017.
Setting the scene – why should we bother? The Problem “Most of us are receiving good, safe care. However as the system continues to struggle with increasingly complex demand, access and cost, future quality is precarious”. Care Quality Commission, State of Care, 2016/17.
Setting the scene – why should we bother? The Problem “Life expectancy in Medway is lower than the national average. Levels of teenage pregnancy, breastfeeding initiation, smoking, diabetes, and cancer mortality in the under-75s are worse than the national average. Violent crime and long- term unemployment are higher”. Medway Health Profile, Public Health England, 2017 .
First Questions As an institution, do we agree that translational research is especially important? o Are we catering for a need that doesn’t really exist? o What commitment have local, external partners shown? What kind of translational research do we want to prioritise? o health care, social care, public health o technological, pharmacological, behavioural o ageing, obesity, long-term conditions, anti-microbial resistance, mental health, primary care o regional, national, international o early-, late-stage What kind of translational research are people currently conducting? o Where are most people at UoK on the translation pathway? We can’t formulate the best strategy without first knowing what everyone is already doing.
Translational Pathway Turning basic research into Introducing ideas and applicable ideas and products products into clinical practice Cooksey Report, 2006
Translational Pathway Turning basic research into Introducing ideas and applicable ideas and products products into clinical practice • • clinical collaboration to access knowledge of regulatory framework relevant expertise and population • industrial collaboration to generate • seed funds to collect preliminary route to market data to help win-over external • funders willingness to accept shared ownership / reduced academic • knowledge of relevant methodology freedom • • shift from a theoretical mindset and evidence that (i) care commissioners tendency to conduct ‘safe academic will fund the innovation, (ii) doctors research’ to one that is more user - will prescribe it, (iii) patients will use it focused and high risk
How could we help colleagues move along the translational pathway? • Run short courses (provided in part by external specialists) to enable students, staff and local health professionals to develop translational skill sets • Offer PhD studentships and mini-conferences to seed new cross-school/institutional collaborations and to develop the next generation of translational scientists • Facilitate access to public health and other external ‘big data’ archives; support open access publication, recommission disease registers • Hold an on-line repository of successful grant and external research ethics applications; provide a forum for sharing knowledge of downstream regulatory and commissioning processes • Peer-review grant applications and potential routes to impact; provide additional strategic steer to KentHealth • Inaugurate an external advisory board to guide and mentor people seeking to move beyond the laboratory • Gate-keep/promote applications to a venture fund • Coordinate the involvement of local non-academic partners (inc. service users) to help drive and evaluate our research for the good of the region
What do we want to achieve today? • Determine the current interest in translational research at UoK • Determine the barriers to conducting translational research at UoK - are there bottlenecks or just not enough people fundamentally interested? • Determine what each School could potentially contribute to / gain from a cross-disciplinary translational group • Discuss what, if anything, a cross-disciplinary group could usefully achieve, identify necessary resources/support, agree the next step.
The UK’s European university Translational Health Symposium 8 th January 2018 Carole Barron LF Fellow Stages of translation – technology readiness Director of Innovation & levels Enterprise
Kent’s current translation levels – based on Kent’s IP TRL 9 - OCT imaging (SPS); Drug production technologies (Biosciences) TRL8 TRL7 – Development of outcome measures (CHSS & MSOP) TRL6 - Drug development (Biosciences) TRL 5 – Encryption and security (EDA) TRL 4 – Galvanic Vestibular Stimulation(Psychology) , Drug production technologies (Biosciences) TRL 3 Cancer diagnostic (MSOP) TRL 2 Screening technologies (Biosciences) and novel materials (SPS) TRL 1 All technologies @ICE_UniKent
Building Capacity in MedTech - Translating innovation from the research base by removing barriers to market Innovation Translation Market End-user (Hot house of ideas) (Adoption) B B A A • Accelerator • Product Funding; development; R R • End-user Academia; • End-user • Licencing of adoption R R training; engagement; technology; Businesses; I I • Analysis and • Prototyping; • End-user Healthcare E E feedback; engagement; Professionals; • Funding – R R • Ideas creation – • Healthcare UKRI, VC & NHS; next generation; S IUK; S Professional engagement; • Analysis and • Compliance; feedback; • Stimulate new ideas; Common Commercialisation Framework (income generating – sustainability)
"Routes to Commercialisation: Understanding IP and how to use it" Purpose: New technologies, processes and knowledge regularly emerge from the University research. IP provides opportunities for collaboration, licensing and impact. Presentations from: Dr Gary Robinson, Senior Commercialisation Manager and Marcus Goodall, Technology Transfer Manager, KIE. When and where: January 23 rd 2018 1-2pm Grimond seminar room 4
The UK’s European university Translational Health Symposium 8 th January 2018 Lucy Druesne Sources of Translational funding Deputy Director of Innovation & Enterprise
Innovate UK - MRC Biomedical Catalyst The aim of the Biomedical Catalyst is to support the development of innovative healthcare products, technologies and processes. Feasibility – The aim of this award is to analyse and evaluate a project’s potential, aimed at supporting the process of decision Primer - The aim of this award is to conduct a technical evaluation of your idea through to proof of concept in a model system – OPEN NOW Deadline: 7 th February 2018 https://apply-for-innovation-funding.service.gov.uk/competition/71/overview Early stage – The aim of this award is to support the development of the proof of concept through to design and early prototype testing. Late stage - The aim of this award is to support projects which test a well-developed concept and show its effectiveness in an environment that is relevant to the use of the product or process. – OPEN NOW Deadline: 7 th February 2018 https://apply-for-innovation-funding.service.gov.uk/competition/79/overview Part of the same initiative as the Biomedical Catalyst from MRC, however this scheme is for the Business led applications.
Innovate UK - Industrial Strategy Challenge Fund (ICSF) Health related Challenges: Accelerating innovative healthcare and medicines: The aim of this challenge is to speed up patient access to new medicines by developing first-of-a-kind technologies for their manufacture. Government will invest £146 million over 4 years in the areas of advanced therapies, medicines and vaccines development and manufacturing. Current calls: ICSF – Medicines Manufacturing CR&D round 2 is due open in March 2018 ICSF – Digital Health Technology Catalyst is due to open January 2018 From data to early diagnosis and precision medicine - The challenge is to combine the wealth of data created by UK researchers with real-world evidence from our health service. The aim is to allow industry to create new products and services that will diagnose diseases earlier and help clinicians choose the best treatment for individual patients . Calls pending Healthy ageing - The challenge is to innovate and address the challenges of ageing while capturing a growing global market, so older people’s aspirations are met and that better, more effective care can support an independent lifestyle as they age. Calls pending Innovate UK and the Knowledge Transfer Network will be holding briefing events for the above calls if you are interested in attending please email entfunding@kent.ac.uk
Recommend
More recommend
